

METABASIS THERAPEUTICS INC  
Form 8-K  
January 14, 2009

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**Form 8-K**

**Current Report Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **January 13, 2009**

---

**Metabasis Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation)

**000-50785**  
(Commission File Number)

**33-0753322**  
(I.R.S. Employer  
Identification No.)

**11119 North Torrey Pines Road**  
**La Jolla, California**  
(Address of principal executive offices)

**92037**  
(Zip Code)

Registrant's telephone number, including area code: **(858) 587-2770**

**Not Applicable.**

Edgar Filing: METABASIS THERAPEUTICS INC - Form 8-K

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events.**

On January 13, 2009, Mark D. Erion, Ph.D., our President, Chief Executive Officer and Chief Scientific Officer, presented a corporate overview during the J.P. Morgan's 27th Annual Healthcare Conference in San Francisco, California. As part of the presentation, Alan Garber, M.D., Ph.D., presented an overview of the results of our Phase 2a clinical study on MB07803, a product candidate for the treatment of type 2 diabetes. A copy of the presentation materials is attached hereto as Exhibit 99.1 and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

<b>Number</b>	<b>Description</b>
99.1	Presentation of Metabasis Therapeutics, Inc. dated January 13, 2009.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**METABASIS THERAPEUTICS, INC.**

By: */s/ Mark D. Erion, Ph.D.*  
Mark D. Erion, Ph.D.  
*President, Chief Executive Officer and Chief  
Scientific Officer*

Date: January 14, 2009

**INDEX TO EXHIBITS**

<b>Number</b>	<b>Description</b>
99.1	Presentation of Metabasis Therapeutics, Inc. dated January 13, 2009.